Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 1, 2013, Pages 7-15

  Ray, Neelanjana ^a   Hwang, Carey ^a   Healy, Matthew D ^a   Whitcomb, Jeannette ^b   Lataillade, Max ^a   Wind Rotolo, Megan ^a   Krystal, Mark ^a   Hanna, George J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

Attachment inhibitor; BMS 626529; BMS 663068; Resistance; Virological response

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 626529; BMS 663068; RITONAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONOTHERAPY; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRAL TROPISM;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; ORGANOPHOSPHATES; PIPERAZINES; PRODRUGS; RNA, VIRAL; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 84883462497     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829726f3     Document Type: Article

References (19)

1. Dau B, Holodniy M. Novel targets for antiretroviral therapy: Clinical progress to date. Drugs. 2009;69:31-50
2. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5:498-503
3. Ho HT, Fan L, Nowicka-Sans B, et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol. 2006;80: 4017-4025
4. Hanna GJ, Lalezari J, Hellinger JA, et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2011;55:722-728
5. Zhou N, Nowicka-Sans B, Zhang S, et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother. 2011;55:729-737
6. Nowicka-Sans B, Gong YF, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012;56:3498-3507
7. Nettles R, Schurmann D, Zhu L, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012;206:1002-1011
8. Toma J, Whitcomb JM, Petropoulos CJ, et al. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4coreceptors. AIDS. 2010;24:2181-2186
9. Jeanmougin F, Thompson JD, Gouy M, et al. Multiple sequence alignment with Clustal X. Trends Biochem Sci. 1998;23:403-405
10. Healy M. Finding homologs to nucleic acid or protein sequences using the framesearch program. Curr Protoc Bioinformatics. 2002;Chapter 3:Unit 3.2
11. Nowicka-Sans B, Gong Y-F, Ho H-T, et al. Antiviral activity of a new small molecule HIV-1 attachment inhibitor, BMS-626529, the parent of BMS-663068. Presented at: 18th Annual Conference on Retroviruses and Opportunistic Infections; 27 February-2 March, 2011; Boston, MA; Poster 518
12. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A. 2003;100:11013-11018
13. Zhou N, Fan L, Ho HT, et al. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Virology. 2010;402:256-261
14. Swinscow TDV, Campbell MJ. Statistics at Square One. 9th ed. London, United Kingdom: BMJ Publishing Group; 1997. Available at: Http://www.bmj.com/ about-bmj/resources-readers/publications/statistics-square-one. Accessed June 3, 2013
15. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005; 191:866-872
16. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172
17. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905
18. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002;18:685-693
19. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and ontreatment HIV-1 isolates. AIDS. 2004;18:1787-1794